Black Rock Inc. Clarus Therapeutics Holdings, Inc. Transaction History

Black Rock Inc.

  • $4.35 Trillion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
SELL
$0.02 - $0.22 $6,476 - $71,236
-323,800 Closed
0 $0
Q2 2022

Aug 12, 2022
BUY
N/A
323,800 New
323,800 $124,000

About Clarus Therapeutics Holdings, Inc.

CRXT Quotes by TradingView
  • Ticker CRXT
  • Exchange NASDAQ
  • Shares Outstandng 52,020,700
  • Market Cap $652
  • Description
  • Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for pr...
More about CRXT
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email